Clinical Trial Update: The Safety, Tolerability and Efficacy of LP-10 in Subjects With Refractory Moderate to Severe Hemorrhagic Cystitis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating safety, tolerability, and efficacy of LP-10 in adults with refractory moderate to severe hemorrhagic cystitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemorrhagic Cystitis

Drugs mentioned

• LP-10 (LP-10)

Snippet

Sponsor: Lipella Pharmaceuticals, Inc. | Conditions: Hemorrhagic Cystitis | Phase 2 | Status: COMPLETED